AIRLINK 72.18 Increased By ▲ 0.49 (0.68%)
BOP 4.93 Decreased By ▼ -0.07 (-1.4%)
CNERGY 4.35 Decreased By ▼ -0.04 (-0.91%)
DFML 28.49 Decreased By ▼ -0.06 (-0.21%)
DGKC 81.30 Decreased By ▼ -1.10 (-1.33%)
FCCL 21.50 Decreased By ▼ -0.45 (-2.05%)
FFBL 33.05 Decreased By ▼ -1.10 (-3.22%)
FFL 9.86 Decreased By ▼ -0.22 (-2.18%)
GGL 10.48 Increased By ▲ 0.36 (3.56%)
HBL 114.00 Increased By ▲ 1.00 (0.88%)
HUBC 140.00 Decreased By ▼ -0.50 (-0.36%)
HUMNL 9.03 Increased By ▲ 1.00 (12.45%)
KEL 4.73 Increased By ▲ 0.35 (7.99%)
KOSM 4.38 Decreased By ▼ -0.12 (-2.67%)
MLCF 37.65 Decreased By ▼ -0.36 (-0.95%)
OGDC 133.70 Decreased By ▼ -0.99 (-0.74%)
PAEL 25.60 Decreased By ▼ -1.02 (-3.83%)
PIAA 23.98 Decreased By ▼ -1.42 (-5.59%)
PIBTL 6.48 Decreased By ▼ -0.07 (-1.07%)
PPL 122.62 Increased By ▲ 0.67 (0.55%)
PRL 27.07 Decreased By ▼ -0.66 (-2.38%)
PTC 13.60 Decreased By ▼ -0.20 (-1.45%)
SEARL 56.62 Increased By ▲ 1.73 (3.15%)
SNGP 69.24 Decreased By ▼ -0.46 (-0.66%)
SSGC 10.34 Decreased By ▼ -0.06 (-0.58%)
TELE 8.45 Decreased By ▼ -0.05 (-0.59%)
TPLP 11.28 Increased By ▲ 0.33 (3.01%)
TRG 61.21 Increased By ▲ 0.31 (0.51%)
UNITY 25.33 Increased By ▲ 0.11 (0.44%)
WTL 1.50 Increased By ▲ 0.22 (17.19%)
BR100 7,630 Decreased By -8.3 (-0.11%)
BR30 24,990 Increased By 18.4 (0.07%)
KSE100 72,602 Decreased By -159.4 (-0.22%)
KSE30 23,539 Decreased By -86.6 (-0.37%)
Business & Finance

Amgen pushes into Asia oncology market with $1.9bn Five Prime buy

  • The deal comes as Amgen looks to expand in the oncology market in Asia-Pacific region, where gastric cancer is more prevalent.
  • It gained a toehold in China in 2019 through a 20.5% stake in Chinese cancer drugmaker BeiGene Ltd for nearly $3 billion.
Published March 4, 2021

Drugmaker Amgen Inc is buying Five Prime Therapeutics for about $1.9 billion and adding a late-stage gastric cancer drug candidate to its line of cancer treatments, the companies said on Thursday.

The deal comes as Amgen looks to expand in the oncology market in Asia-Pacific region, where gastric cancer is more prevalent.

It gained a toehold in China in 2019 through a 20.5% stake in Chinese cancer drugmaker BeiGene Ltd for nearly $3 billion.

Through the latest deal, Amgen will get access to Five Prime's lead drug candidate, bemarituzumab, which is ready to enter a late-stage study for treating advanced gastric cancer.

"While gastric cancer may be a small market in the United States, it could provide a significant opportunity in Asia", Truist Securities analyst Robyn Karnauskas said.

Amgen will also get a royalty share on future sales of bemarituzumab in China, where Five Prime has a marketing and development deal with Zai Lab Ltd.

The treatment had shown improved overall survival and reduced risk of gastric cancer progression in a mid-stage study.

Bemarituzumab works by targeting a gene called FGFR2b, which when mutated may cause the overexpression of a protein involved in cell division.

The treatment is an addition to Amgen's two other gastric cancer drug candidates, AMG 910 and AMG 199, which are in early-stage trials.

Amgen will pay $38 per Five Prime share, representing a premium of nearly 79% to the company's last closing price of $21.26.

Five Prime shares surged 78% and Amgen added 0.6% in early trading.

Comments

Comments are closed.